Lifitegrast, also known as SAR-1118, is an LFA-1 antagonist intended for the treatment of vascular complications of the eye. Lifitegrast inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), thus lessening overall inflammatory responses.
Integrin Related Prodcuts:
Cilengitide trifluoroacetate; Cilengitide; Leukadherin 1; Vedolizumab; Eptifibatide; A286982